EP0766680A1 - Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists - Google Patents

Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists

Info

Publication number
EP0766680A1
EP0766680A1 EP96912004A EP96912004A EP0766680A1 EP 0766680 A1 EP0766680 A1 EP 0766680A1 EP 96912004 A EP96912004 A EP 96912004A EP 96912004 A EP96912004 A EP 96912004A EP 0766680 A1 EP0766680 A1 EP 0766680A1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
amino
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96912004A
Other languages
German (de)
French (fr)
Inventor
Daniele Fancelli
Carla Caccia
Dino Severino
Fabrizio Vaghi
Mario Varasi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of EP0766680A1 publication Critical patent/EP0766680A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • the present invention relates to the use 'of substituted dihydrobenzofuran derivatives which act as 5-HT 4 receptor agonists in the treatment of gastrointestinal disorders and CNS disorders, to certain novel compounds having 5-HT 4 receptor agonist activity, to a process for their preparation and to pharmaceutical compositions containing them.
  • a non classical 5-hydroxytriptamine receptor has been designed (Trends Pharmacol. Sci. (1992) 13, 141-5) as the 5-HT 4 receptor.
  • 5-HT 4 receptor agonists resulted active in appropriate animal behavioural tests for memory dysfunctions (Ghelardini et al. 19 th C.I.N.P. Congress, hashington, June 1994 ; Ghelardini et al . 10 th European Society for Neurochemistry, Jerusalem, August 1994) .
  • International patent application WO 93/16072 describes 5- HT 4 receptor antagonists derived from the benzopyran, benzothiopyran or benzofuran nucleus.
  • the compounds of the invention can be useful in all the pathologies wherein a stimulation of the 5-HT 4 receptors is needed and therefore, the compounds of the invention can be useful, for example, as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) and gastroparesis, and/or also in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
  • GORD gastro-oesophageal reflux disease
  • the present invention relates to dihyrobenzofuran derivatives of formula (I)
  • R lf R 2 and R 3 are, each independently, hydrogen, C ⁇ Cg alkyl, halogen, hydroxy, C j - ⁇ alkoxy, amino, C 1 -C 4 alkylamino or C ⁇ di-alkylamino;
  • X is 0, NH or CH 2 ;
  • Z is a group (a) , (b) , (c) or (d)
  • R 4 is hydrogen , C ⁇ Cg alkyl, benzyl, cyclohexylmethyl or - CH 2 -C-_ 2 -S0 2 N__-R 6 in which R 6 is C ⁇ Cg alkyl or benzyl ;
  • R 5 is Ci-Cg alkyl
  • T is halogen ; provided that, when Z is defined under (c) , then X is O or CH 2 , and their pharmaceutically acceptable salts, for use as 5-HT 4 agonists.
  • the compounds of formula (I) can therefore be useful in the treatment of all the pathologies wherein a stimulation of the 5-HT 4 receptor is needed.
  • the compounds of formula (I) may be useful as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, for example, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.
  • GORD gastro-oesophageal reflux disease
  • the compounds of formula (I) may also be useful, by virtue of their 5-HT 4 agonist properties, as cognition activators, in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
  • the alkyl, alkoxy and alkylamino groups may be branched or straight groups.
  • alkyl groups include methyl, ethyl, n- and iso-propyl, n - , iso- , sec- and tert- butyl.
  • C -C. alkoxy groups include methoxy and ethoxy.
  • a C x -C 4 alkylamino group is, in particular, methylamino or ethylamino.
  • a C 1 -C 4 di-alkylamino group is, in particular, dimethylamino or diethylamino.
  • Halogen includes fluorine, bromine, chlorine or iodine, in particular, chlorine or bromine.
  • the pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with inorganic, e.g. hydrochloric, hydrobromic, sulphuric, and phosphoric acids, or organic, e.g. acetic, propionic, lactic, oxalic, malic, maieic, tartaric, citric, benzoic, mandelic, salicylic and fumaric acids.
  • Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) or (b) include quaternary derivatives such as, e.g., the compounds quaternised by compounds of formula R * -W wherein R- is C x - C 6 alkyl or phenyl-Ci-Cgalkyl and W is a radical corresponding to an anion of an acid.
  • R x is C--C 4 alkyl or phenyl-C 1 -C 4 alkyl, in particular it is methyl, ethyl, n-propyl, ⁇ _-butyl, benzyl or phenylethyl .
  • W is a halide such as, e.g., chloride, bromide or iodide.
  • Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) , (b) or (c) also include internal salts, such as, e.g. N-oxides.
  • the compounds of formula (I) , their pharmaceutically acceptable salts, (including quaternary derivatives and N- oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are also object of the present invention.
  • Compounds of formula (I) wherein Z is a group (c) contain an asymmetric carbon atom and, for this reason, they can exist either as a mixture of optical isomers (racemic mixture) or as a single optical isomers (enantiomers) .
  • the enantiomers can be separately synthesised from optically pure starting material or separated from the racemic mixture in a conventional manner.
  • the present invention also include within its scope both the metabolites and the pharmaceutically acceptable bio- precursors (otherwise known as pro-drugs) of the compounds of formula (I) .
  • This invention also refers to a preferred class of compounds within formula (I), as novel compounds. These compounds, which form a further object of the invention, are compounds of formula (I)
  • R x is hydrogen
  • R 2 is chlorine or bromine; R 3 is amino; X is 0 or NH; Z is a group (a) , (b) , (c) or (d) :
  • R 4 is C 3 -C 5 alkyl or -CH 2 -CH 2 -S0 2 NH-CH 3 ;
  • R 5 is C 3 -C 3 alkyl;and T is chlorine or bromine; provided that, when Z is defined under (c) , then X is O; and their pharmaceutically acceptable salts.
  • preferred compounds according to the invention are the following: N- tl-butyl-1-azabicyclo [2, 2,2] oct-3-yl] -4-amino-5-chloro- 2 , 3 -dihydrobenzo [b] furan-7-carboxamide bromide; (1-azabicyclo [2,2,2] oct-3-yl) -4-amino-5-chloro-2, 3 -dihydro ⁇ benzo [b] furan- 7 -carboxylate; (i-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2, 3-dihydro- benzo [b] furan-7-carboxylate;
  • the compounds of formula (I) can be obtained by a process comprising : A) reacting a compound of formula (II)
  • E is OH, Cl, Br or 1-imidazolyl
  • R x , R 2 and R 3 are, each independently, hydrogen, C ⁇ Cg alkyl, halogen, hydroxy, ⁇ C- . -C 4 alkoxy, amino, C- . - ⁇ alkylamino or C- . -C 4 di-alkylamino, with an amine or an alcohol of formula (III) , (IV) or (V)
  • Q is OH or NH 2 ; n is 1,2,3 or 4; m is 0 or 1; q is 0,1 or 2; and
  • R 4 is hydrogen, Ci-Cg alkyl, benzyl, cyclohexylmethyl or
  • R 6 is C ⁇ Cg alkyl or benzyl so obtaining a compound of formula (I) wherein R l t R 2 , R 3 and R 6 are as defined above, X is NH or O and Z is a group
  • Y is OH, Cl, Br or CH 3 -NH-OCH 3
  • R-, R 2 and R 3 are are as defined above, with an organometallic derivative of formula (VII) , (VIII) or (IX)
  • M is MgBr, MgCl or Li
  • n, m, q, R 4 and R 5 are as defined above, so obtaining a compound of formula (I) wherein R x , R 2 and R 3 are as defined above, X is CH 2 and Z is a group (a) , (b) or (c) ; or C) reacting a compound of formula (X)
  • R x , R 2 , R 3 and X are as defined above, and X is NH, 0 or CH 2 , with an alkyl halide of formula R 5 T wherein R 5 is alkyl and T is halogen, so obtaining a compound of formula
  • CH 2 and Z is a group (d) ; and, if desired, when a compound of formula (I) contains an asymmetric carbon atom,
  • (II) can be reacted with an alcohol or an amine of formula (III) , (IV) or (V) in a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofurane or acetonitrile, at a temperature ranging from about 0°C to about the reflux temperature of the mixture, in the presence of a proton scavenger such as, for instance, t-riethylamine, sodium hydrogen carbonate or potassium carbonate.
  • a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofurane or acetonitrile
  • reaction of a compound of formula (VI) with a compound of formula (VII) , (VIII) or (IX) under step B) can also be carried out according to well known methods in the art.
  • an acyl halide of formula (VI) can be reacted with a Grignard reactive of formula (VII) , (VIII) or (IX) in a suitable organic solvent such as, e.g., tetrahydrofuran or diethyl ether in the presence of, e.g., Fe (acetylacetonate) 3 or Cul, at a temperature ranging from about -78°C to about 30°C.
  • reaction of a compound of formula (X) with an alkyl halide R 5 T under step C) can be carried out according to standard methodologies.
  • a compound of formula (X) can be reacted with a compound R 5 T as defined above, in the presence of a suitable organic solvent such as, e.g., methanol or ethanol, at a temperature ranging from about 30°C to about the reflux temperature of the mixture.
  • a suitable organic solvent such as, e.g., methanol or ethanol
  • the acid derivatives (II) and (VI) are either known products (EP 0 234 872 Al Adria Laboratories Inc. ) or may be prepared from the corresponding acids by methods well known in the art.
  • the alcohols and amines of formulae (III) , (IV) and (V) are either commercially available or known products.
  • the organometallic derivatives of formulae (VII) , (VIII) and (IX) can be prepared by standard methodologies from the corresponding alkyl halides which are either commercially available products or can be easily prepared from the corresponding alcohols of formulae (III), (IV) and (V) .
  • the compounds of formula (X) wherein X is NH are known compounds (EP 0 234 872 Al Adria Laboratories Inc.).
  • the alkyl halides of formula R S T are commercially available products.
  • the compounds of the present invention are potent agonists of 5-HT (serotonin) on 5-HT 4 receptors and can therefore be used in the treatment of the pathologies wherein a stimulation of the 5-HT 4 receptor is needed.
  • 5-HT 4 agonists are known being stimulant of gastrointestinal motility
  • the compounds of the present invention can be useful as therapeutic prokinetic agents, for example, in the treatment of gastrointestinal disease such as, for instance, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.
  • GORD gastro-oesophageal reflux disease
  • 5-HT 4 receptor affinity of the compounds of the present invention was determined by the inhibition of the binding of the 5-HT 4 receptor radioligand [ 3 H] -GR-113808 in rat striatum, according to the method of Grossman et al .
  • IC 50 concentration of the tested compound which forces the displacements of 50% of the bound radioligand concentration, obtained in the absence of inhibitor.
  • [L] radioligand concentration
  • Kd dissociation constant of the radioligand-receptor complex.
  • EC 50 efficacy concentration: concentration of the tested compound which induces 50% of the max. response (in this case 50% of the max. relaxation) .
  • i.a. intrinsic activity: max. response/max response of the natural agonist (in this case max. relaxation/5-HT max.relaxation) .
  • the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous injection or infusion.
  • dosage forms e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous injection or infusion.
  • the dosage depends on the age, weight,, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compound of the invention FCE 29034A may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.
  • the invention includes pharmaceutical compositions comprising a compound of the invention as an active principle in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent) .
  • a pharmaceutically acceptable excipient which can be a carrier or a diluent.
  • the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
  • the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
  • diluents e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidon
  • a starch alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations.
  • Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
  • the liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspensions or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride.
  • the solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions.
  • the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • a pharmaceutically acceptable carrier e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
  • Volatilies were evaporated under reduced pressure and the residue was taken up with water and ethyl acetate; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 1.0 of raw material, which was partially purified by column chromatography over silica gel (eluant chloroform/methyl alcohol/ammonia solution 30% 46:4:0.1) .
  • the carboxamide was conveniently isolated as its hydrochloride by adding to the free base in aceton/isopropyl alcohol 1 equivalent of hydrochloric acid in isopropyl alcohol.
  • preparation can be made of capsules having the following composition: N- (1-piperidyl)ethyl-4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride ' hydrate 50mg talc 2mg starch 2mg microcristalline cellulose 6mg magnesium stearate lmg

Abstract

The present invention relates to the use of substituted dihydrobenzofuran derivatives having 5-HT4 receptor agonist activity, which act as therapeutic prokinetic agents in treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis. The compounds of the invention can also be useful in the treatment of CNS disorders, characterized by learning and/or memory dysfunctions. Several of these substituted dihydrobenzofuran derivatives are novel compounds and, as such, constitute a further object of the invention, together with the process for their preparation and the pharmaceutical compositions containing them.

Description

SUBSTITUTED DIHYDROBENZOFURAN DERIVATIVES AS 5-HT4 AGONISTS
The present invention relates to the use 'of substituted dihydrobenzofuran derivatives which act as 5-HT4 receptor agonists in the treatment of gastrointestinal disorders and CNS disorders, to certain novel compounds having 5-HT4 receptor agonist activity, to a process for their preparation and to pharmaceutical compositions containing them. A non classical 5-hydroxytriptamine receptor has been designed (Trends Pharmacol. Sci. (1992) 13, 141-5) as the 5-HT4 receptor.
The prokinetic action of the substituted benzamide metoclopramide, which has long been in clinical use as a stimulant of gastrointestinal motility, is believed to be on the basis of its agonist effect on the 5-HT4 receptor
(Drug Design & Delivery (1988) 3, 273-295) .
Some 5-HT4 receptor agonists resulted active in appropriate animal behavioural tests for memory dysfunctions (Ghelardini et al. 19th C.I.N.P. Congress, hashington, June 1994 ; Ghelardini et al . 10th European Society for Neurochemistry, Jerusalem, August 1994) . International patent application WO 93/16072 describes 5- HT4 receptor antagonists derived from the benzopyran, benzothiopyran or benzofuran nucleus.
International patent application WO 94/08995 relates to novel carboxylate or carboxamides of benzofuran or dibenzofuran having 5-HT4 antagonist activity.
We have identified a class of substituted dihydrobenzofuran carboxylic acid derivatives which possess 5-HT4 receptor agonist properties, despite their structural analogies with the closest prior art compounds such as, e.g., those disclosed in WO 93/16072 and WO 94/08995 having 5-HT4 antagonist activity.
By virtue of their 5-HT4 agonist activity, the compounds of the invention can be useful in all the pathologies wherein a stimulation of the 5-HT4 receptors is needed and therefore, the compounds of the invention can be useful, for example, as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, e.g., dyspepsia, gastro-oesophageal reflux disease (GORD) and gastroparesis, and/or also in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
Accordingly, the present invention relates to dihyrobenzofuran derivatives of formula (I)
(I) wherein
Rlf R2 and R3 are, each independently, hydrogen, C^Cg alkyl, halogen, hydroxy, Cj-^ alkoxy, amino, C1-C4 alkylamino or C^^ di-alkylamino; X is 0, NH or CH2; Z is a group (a) , (b) , (c) or (d)
(CH.)„— (CH,
V_/ (a)
wherein n is 1, 2, 3 or 4; m is zero or 1; q is zero, 1 or 2;
R4 is hydrogen , C^Cg alkyl, benzyl, cyclohexylmethyl or - CH2-C-_2-S02N__-R6 in which R6 is C^ Cg alkyl or benzyl ;
R5 is Ci-Cg alkyl ; and
T is halogen ; provided that, when Z is defined under (c) , then X is O or CH2, and their pharmaceutically acceptable salts, for use as 5-HT4 agonists. The compounds of formula (I) can therefore be useful in the treatment of all the pathologies wherein a stimulation of the 5-HT4 receptor is needed. As an example, the compounds of formula (I) may be useful as therapeutic prokinetic agents in the treatment of gastrointestinal disorders such as, for example, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis.
The compounds of formula (I) may also be useful, by virtue of their 5-HT4 agonist properties, as cognition activators, in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
The alkyl, alkoxy and alkylamino groups may be branched or straight groups.
Representative examples of alkyl groups include methyl, ethyl, n- and iso-propyl, n - , iso- , sec- and tert- butyl.
Representative examples of C -C. alkoxy groups include methoxy and ethoxy.
A Cx-C4 alkylamino group is, in particular, methylamino or ethylamino. A C1-C4 di-alkylamino group is, in particular, dimethylamino or diethylamino.
Halogen includes fluorine, bromine, chlorine or iodine, in particular, chlorine or bromine. The pharmaceutically acceptable salts of the compounds of formula (I) include acid addition salts with inorganic, e.g. hydrochloric, hydrobromic, sulphuric, and phosphoric acids, or organic, e.g. acetic, propionic, lactic, oxalic, malic, maieic, tartaric, citric, benzoic, mandelic, salicylic and fumaric acids.
Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) or (b) include quaternary derivatives such as, e.g., the compounds quaternised by compounds of formula R*-W wherein R- is Cx- C6 alkyl or phenyl-Ci-Cgalkyl and W is a radical corresponding to an anion of an acid.
Preferably, Rx is C--C4 alkyl or phenyl-C1-C4alkyl, in particular it is methyl, ethyl, n-propyl, ι_-butyl, benzyl or phenylethyl . Preferably, W is a halide such as, e.g., chloride, bromide or iodide.
Examples of pharmaceutically acceptable salts of the compounds of formula (I) wherein Z is a group (a) , (b) or (c) also include internal salts, such as, e.g. N-oxides. The compounds of formula (I) , their pharmaceutically acceptable salts, (including quaternary derivatives and N- oxides) may also form pharmaceutically acceptable solvates, such as hydrates, which are also object of the present invention. Compounds of formula (I) wherein Z is a group (c) contain an asymmetric carbon atom and, for this reason, they can exist either as a mixture of optical isomers (racemic mixture) or as a single optical isomers (enantiomers) . The enantiomers can be separately synthesised from optically pure starting material or separated from the racemic mixture in a conventional manner.
The present invention also include within its scope both the metabolites and the pharmaceutically acceptable bio- precursors (otherwise known as pro-drugs) of the compounds of formula (I) .
This invention also refers to a preferred class of compounds within formula (I), as novel compounds. These compounds, which form a further object of the invention, are compounds of formula (I)
wherein
Rx is hydrogen;
R2 is chlorine or bromine; R3 is amino; X is 0 or NH; Z is a group (a) , (b) , (c) or (d) :
"(CH,).— .(CHJ.
(a)
wherein n is 2 or 3; m is zero or 1; q is 1 or 2;
R4 is C3-C5 alkyl or -CH2-CH2-S02NH-CH3;
R5 is C3-C3 alkyl;and T is chlorine or bromine; provided that, when Z is defined under (c) , then X is O; and their pharmaceutically acceptable salts. Examples of preferred compounds according to the invention are the following: N- tl-butyl-1-azabicyclo [2, 2,2] oct-3-yl] -4-amino-5-chloro- 2 , 3 -dihydrobenzo [b] furan-7-carboxamide bromide; (1-azabicyclo [2,2,2] oct-3-yl) -4-amino-5-chloro-2, 3 -dihydro¬ benzo [b] furan- 7 -carboxylate; (i-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2, 3-dihydro- benzo [b] furan-7-carboxylate;
(1-piperidyl) propyl-4-amino-5-chloro-2 , 3 -dihydrobenzo [b] furan- 7 -carboxylate;
(1-piperidyl) ethyl-4-amino-5-chloro-2 , 3 -dihydrobenzo [b] furan- 7 -carboxylate ;
N- [ ( 1 -butyl -piper id- 4 -yl) methyl] -4 -amino-5-chloro-2 , 3- dihydrobenzo [b] furan-7-carboxamide;
N- t (1 -piper idyl )propyl] -4-amino-5-chloro-2, 3 -dihydrobenzo [b] furan-7-carboxamide; and N- [ (1-piperidyl) ethyl] -4-amino-5-chloro-2 , 3 -dihydrobenzo [b] furan-7-carboxamide; if the case either as a single isomer or as a mixture of isomers thereof, and the pharmaceutically acceptable salts thereof . The compounds of formula (I) can be obtained by a process comprising : A) reacting a compound of formula (II)
R3 (II) wherein
E is OH, Cl, Br or 1-imidazolyl, and
Rx , R2 and R3 are, each independently, hydrogen, C^Cg alkyl, halogen, hydroxy, ■ C-.-C4 alkoxy, amino, C-.-^ alkylamino or C-.-C4 di-alkylamino, with an amine or an alcohol of formula (III) , (IV) or (V)
Q—(CH.). .(CH-)„
(III)
HO
(V) wherein ■ N—N
Q is OH or NH2; n is 1,2,3 or 4; m is 0 or 1; q is 0,1 or 2; and
R4 is hydrogen, Ci-Cg alkyl, benzyl, cyclohexylmethyl or
-CH2-CH2-S02-NH-R6 in which R6 is C^Cg alkyl or benzyl so obtaining a compound of formula (I) wherein Rl t R2, R3 and R6 are as defined above, X is NH or O and Z is a group
(a) , (b) or (c) ; or
B) reacting a compound of formula (VI)
(VI) wherein
Y is OH, Cl, Br or CH3-NH-OCH3, and R-, R2 and R3 are are as defined above, with an organometallic derivative of formula (VII) , (VIII) or (IX)
M—(CH,).—N (CH,)m
(VII)
wherein
M is MgBr, MgCl or Li, and n, m, q, R4 and R5 are as defined above, so obtaining a compound of formula (I) wherein Rx, R2 and R3 are as defined above, X is CH2 and Z is a group (a) , (b) or (c) ; or C) reacting a compound of formula (X)
wherein Rx , R2, R3 and X are as defined above, and X is NH, 0 or CH2, with an alkyl halide of formula R5T wherein R5 is alkyl and T is halogen, so obtaining a compound of formula
(I) wherein R^ R2, R3 are as defined above, X is 0, NH, or
CH2 and Z is a group (d) ; and, if desired, when a compound of formula (I) contains an asymmetric carbon atom,
D) resolving the racemic mixture of a compound of formula
(I) into the single isomers; and/or, if desired,
E) converting a compound of formula (I) into a pharmaceutically acceptable salt thereof. The reaction of a compound of formula (II) with a compound of formula (III) , (IV) or (V) under step A) is an analogy process and can be carried out according to well known methods in the art. For instance, an acyl halide of formula
(II) can be reacted with an alcohol or an amine of formula (III) , (IV) or (V) in a suitable organic solvent such as, for instance, dichloromethane, tetrahydrofurane or acetonitrile, at a temperature ranging from about 0°C to about the reflux temperature of the mixture, in the presence of a proton scavenger such as, for instance, t-riethylamine, sodium hydrogen carbonate or potassium carbonate.
The reaction of a compound of formula (VI) with a compound of formula (VII) , (VIII) or (IX) under step B) can also be carried out according to well known methods in the art. For instance, an acyl halide of formula (VI) can be reacted with a Grignard reactive of formula (VII) , (VIII) or (IX) in a suitable organic solvent such as, e.g., tetrahydrofuran or diethyl ether in the presence of, e.g., Fe (acetylacetonate) 3 or Cul, at a temperature ranging from about -78°C to about 30°C.
The reaction of a compound of formula (X) with an alkyl halide R5T under step C) can be carried out according to standard methodologies. For instance, a compound of formula (X) can be reacted with a compound R5T as defined above, in the presence of a suitable organic solvent such as, e.g., methanol or ethanol, at a temperature ranging from about 30°C to about the reflux temperature of the mixture. The carboxylic acids of formulae (II) and (VI) wherein E and Y are OH are either commercially available or known products.
The acid derivatives (II) and (VI) are either known products (EP 0 234 872 Al Adria Laboratories Inc. ) or may be prepared from the corresponding acids by methods well known in the art. The alcohols and amines of formulae (III) , (IV) and (V) are either commercially available or known products. The organometallic derivatives of formulae (VII) , (VIII) and (IX) can be prepared by standard methodologies from the corresponding alkyl halides which are either commercially available products or can be easily prepared from the corresponding alcohols of formulae (III), (IV) and (V) . The compounds of formula (X) wherein X is NH are known compounds (EP 0 234 872 Al Adria Laboratories Inc.). The alkyl halides of formula RST are commercially available products.
The separation of a mixture of isomers of a compound of the invention into single isomers and the conversion of a compound of formula (I) into a pharmaceutically acceptable salt thereof can be carried out according to well known methods in the art.
As already said, the compounds of the present invention are potent agonists of 5-HT (serotonin) on 5-HT4 receptors and can therefore be used in the treatment of the pathologies wherein a stimulation of the 5-HT4 receptor is needed. In particular, as 5-HT4 agonists are known being stimulant of gastrointestinal motility, the compounds of the present invention can be useful as therapeutic prokinetic agents, for example, in the treatment of gastrointestinal disease such as, for instance, dyspepsia, gastro-oesophageal reflux disease (GORD) or gastroparesis. In addition, in view of the fact that 5-HT4 receptors are believed to be involved in synaptic plasticity events and in memory processes (CNS Drugs (1994) 1, 6-15) , and that it has been demonstrated that 5-HT4 receptor stimulation facilitates in vivo acetylcholine release in rat frontal cortex (NeuroReport (1994) 5, 1230-2) , another application of the compounds of the invention may also be as cognition activators in the treatment of CNS disorders characterized by learning and/or memory dysfunctions. 5-HT4 receptor affinity of the compounds of the present invention was determined by the inhibition of the binding of the 5-HT4 receptor radioligand [3H] -GR-113808 in rat striatum, according to the method of Grossman et al . (Br.J.Pharmacol. , 1993, 109,618-624) . The activity of the compounds of the present invention as 5-HT4 agonists was evaluated "in vitro" by the receptor- mediated relaxation responses of rat, carbachol precontracted oesophageal muscolaris mucosae, following the method of Baxter et al. , (Naunhyn Schmiedeberg' s Arch. Pharmacol., 1991, 343, 439-446) .
As an example, a representative group of compounds according to this invention, namely
(S) - (+) -N- [l-butyl-l-azabicyclo[2,2,2]oct-3-yl] -4-amino- 5-chloro-2, 3-dihydrobenzo [b] furan-7-carboxamide bromide monohydrate (internal code FCE 28773A) ;
(1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2, 3- dihydrobenzo[b] furan-7-carboxylate hydrochloride (internal code FCE 29029A) ; N- [ (1-butyl-piperid-4-yl)methyl] -4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride (internal code FCE 29030A) ;
(1-piperidyl) ethyl-4-amino-5-chloro-2, 3-dihydrobenzo[b] furan-7-carboxylate hydrochloride hemihydrate (internal code FCE 29032A) ; N- [ (1-piperidyl)ethyl] -4-amino-5-chloro-2, 3-dihydrobenzo
[b] furan-7-carboxamide hydrochloride hydrate (internal code FCE 29033A) ;
(1-piperidyl)propyl-4-amino-5-chloro-2,3- dihydrobenzo [b] furan-7-carboxylate hydrochloride hemihydrate (internal code FCE 29031A) ;
N- [ (1-piperidyl)propyl] -4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride hydrate
(internal code FCE 29034A) and
(S) - (+) - (l-azabicyclo[2,2,2]oct-3-yl) -4-amino-5-chloro- 2,3-dihydrobenzo[b] furan- -carboxylate hydrochloride (internal code FCE 28797A) ; were tested according to the methods described above and the obtained results are reported on Table 1. Table 1
IC.
K, = l + ΓLI
Kd where
IC50 = concentration of the tested compound which forces the displacements of 50% of the bound radioligand concentration, obtained in the absence of inhibitor. [L] = radioligand concentration Kd = dissociation constant of the radioligand-receptor complex.
EC50 = efficacy concentration: concentration of the tested compound which induces 50% of the max. response (in this case 50% of the max. relaxation) . i.a. = intrinsic activity: max. response/max response of the natural agonist (in this case max. relaxation/5-HT max.relaxation) .
The tabulated results clearly show that the compounds of the invention exhibit high affinity for the 5-HT4 receptor sites and, in the same time, are particularly effective in promoting 5-HT4 receptor activity.
The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscolarly, or by intravenous injection or infusion.
The dosage depends on the age, weight,, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compound of the invention FCE 29034A may range from about 1 to about 500 mg pro dose, from 1 to 5 times daily.
The invention includes pharmaceutical compositions comprising a compound of the invention as an active principle in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent) . The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension. The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
The suspensions or solutions for intramuscolar injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desidered, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, acqueous, isotonic saline solutions.
The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin. The following examples illustrate but do not limit the invention.
Example 1
A mixture of 4-amino-5-chloro-2, 3-dihydrobenzo [b] furan-7- carboxylic acid (0.700g , 3.28 mmol) and carbonyldiimidazol (0.580g , 3.60 mmol) in 10 ml of anhydrous tetrahydrofuran was heated at 40°C for 1.5h. Afterward (1- piperidyDethylamine (0.427ml , 4.92mmol) in 5ml of tetrahydrofuran was added, the mixture was heated for additional 2h and stirred at 22°C for 16h. Volatilies were evaporated under reduced pressure and the residue was taken up with water and ethyl acetate; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 1.0 of raw material, which was partially purified by column chromatography over silica gel (eluant chloroform/methyl alcohol/ammonia solution 30% 46:4:0.1) . The carboxamide was conveniently isolated as its hydrochloride by adding to the free base in aceton/isopropyl alcohol 1 equivalent of hydrochloric acid in isopropyl alcohol. Precipitated solid was filtered, washed with c.:.-._hy_ ether and dried, yielding 746mg (60%) of N- [ (1-piperidyl) ethyl] -4-amino-5-chloro-2 , 3 - dihydrobenzo [b] furan-7-carboxamide hydrochloride hydrate as a colorless solid (m.p. = 237-239°C) . Analogously, the following compounds were prepared :
N- t (l-piperidyl)propyl] -4-amino-5-chloro-2 , 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride hydrate (m.p. 192-194°C) ; and N- [ (l-butyl-piperid-4-yl) methyl] -4-amino-5-chloro-2 , 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride (m.p.260- 262°C) . Example 2
A mixture of 4-amino-5-chloro-2, 3-dihydrobenzo [b] furan-7- carboxylic acid (1.61g , 7.56 mmol) and carbonyldiimidazol (1.35g , 8.32 mmol) in 15 ml of anhydrous tetrahydrofuran was heated at 40°C for 1.5h. Afterward a solution of N- (1- butyl-piperid-4-yl)methyl alcohol (2.59g , 15.1mmol) and 1, 8-diazabicyclo [5,4> 0]undec-7-en (DBU) (1.13ml , 7.56 mmol) in 10ml of tetrahydrofuran was added and the mixture was heated for additional 2.5h. Volatilies were evaporated under reduced pressure and the residue was taken up with water and diethyl ether; the layers were separated, the organic layer was dried over anhydrous sodium sulphate and evaporated to give 3.5g of raw material, which was purified by column chromatography over silica gel (eluant chloroform/methyl alcohol 46:4) yielding 1.5g (54%) of (1- butyl-piperid-4-yl) ethyl-4-amino-5-chloro-2, 3-dihydrobenzo [b] furan-7-carboxylate (m.p. = 124-126°C) as a colorless solid. Analogously, the following compounds can be prepared :
(1-piperidyl ) ethyl-4-amino-5-chloro-2 , 3 -dihydrobenzo [b] furan-7-carboxylate (m.p. = 152-154°C) ; (1-piperidyl ) propyl-4-amino-5-chloro-2 , 3-dihydrobenzo [b] furan-7-carboxylate; and (S) - (+) - (l-azabicyclo[2,2,2]oct-3-yl) -4-amino-5-chloro- 2, 3-dihydrobenzo [b] furan-7-carboxylate. Example 3
1 equivalent of hydrochloric acid in isopropyl alcohol was added at 5°C to a stirred solution of (1-piperidyl)propyl 4-amino-5-chloro-2, 3-dihydrobenzo [b] f ran-7-carboxylate (337mg , 0.996mmol) in aceton . Precipitated solid was was filtered, washed with diethyl ether and dried, yielding 342mg (89%) of (1-piperidyl)propyl 4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxylate hydrochloride hemihydrate as a colorless solid (m.p. = 226-228°C) . Analogously, the following compounds were prepared : (1-piperidyl) ethyl-4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxylate hydrochloride hemihydrate (m.p. 255-257°C) ; (l-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxylate hydrochloride (m.p. = 238-240°C) ; and
(S) - (+) - (1-azabicyclo [2,2,2] oct-3-yl) -4-amino-5-chloro- 2, 3-dihydrobenzo [b] furan-7-carboxylate hydrochloride (m.p. 283.5-284.5); [a] D" = +82 (c = 0.94 , D F) .
Example 4
A mixture of (S) - (+) - [1-azabicyclo [2, 2,2] oct-3-yl] -4- amino-5-chloro-2, 3-dihydrobenzo[b] furan-7-carboxamide (0.508g , 1.58mmol) and n-butylbromide (0.169ml , 1.58mmol) in ethyl alcohol was heated under reflux for
16h. The solvent was removed under reduced pressure, the residue was purified by column chromatography over silica gel (eluent chloroform/ methyl alcohol 4:1) and crystallized by water giving 0.43g (60%) of (S) - (+) -N- [1- butyl-1-azabicyclo [2,2,2] oct-3-yl] -4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide bromide monohydrate as an amorphous colorless solid ; [α]D 23 = +36 (c = 0.94 , DMF) . Example 5
With the usual methods of pharmaceutical technique, preparation can be made of capsules having the following composition: N- (1-piperidyl)ethyl-4-amino-5-chloro-2, 3- dihydrobenzo [b] furan-7-carboxamide hydrochloride ' hydrate 50mg talc 2mg starch 2mg microcristalline cellulose 6mg magnesium stearate lmg

Claims

1. A dihydrobenzofuran derivative of formula (I)
wherein
R1, R2 and R3 are, each independently, hydrogen,
C1-C6 alkyl, halogen, hydroxy, C1-C4 alkoxy, amino,
C1-C4 alkylamino or C1-C4, di-alkylamino;
X is O, NH or CH2;
Z is a group (a), (b), (c) or (d)
wherein
n is 1, 2, 3 or 4;
m is zero or 1;
q is zero, 1 or 2;
R4 is hydrogen , C1-C6 alkyl, benzyl, cyclohexylmethyl or -CH2-CH2-SO2NH-R6 in which R6 is C1-C6 alkyl or benzyl; R5 is C1-C6 alkyl; and
T is halogen;
provided that, when Z is defined under (c), then X is 0 or CH2; or a pharmaceutically acceptable salt thereof, for use as a 5-HT4 receptor agonist.
2. A dihydrobenzofuran derivative of formula (I):
wherein
R1 is hydrogen;
R2 is chlorine or bromine;
R3 is amino;
X is O or NH;
Z is a group (a), (b), (c) or (d) wherein
n is 2 or 3;
m is zero or 1;
q is 1 or 2;
R4 is C3-C5 alkyl or -CH2-CH2-SO2NH-CH3;
R5 is C3-C5 alkyl; and
T is chlorine or bromine;
provided that, when Z is defined under (c), then X is O; or a pharmaceutically acceptable salt thereof. 3. A compound as claimed in claim 2, selected from:
N-[1-butyl-1-azabicyclo[2,2,2]oct-3-yl]-4-amino-5-chloro- 2,3-dihydrobenzo[b]furan-7-carboxamide bromide;
(1-azabicyclo[2,2,2]oct-3-yl)-4-amino-5-chloro-2,3- dihydrobenzo[b]furan-7-carboxylate;
(1-butyl-piperid-4-yl)methyl-4-amino-5-chloro-2,3- dihydrobenzo[b]furan-7-carboxylate;
(1-piperidyl)propyl-4-amino-5-chloro-2,3-dihydrobenzo [b] furan-7-carboxylate;
(1-piperidyl)ethyl-4-amino-5-chloro-2,3-dihydrobenzo
[b]furan-7-carboxylate;
N-[(1-butyl-piperid-4-yl)methyl]-4-amino-5-chloro-2,3- dihydrobenzo[b]furan-7-carboxamide;
N-[(1-piperidyl)propyl] 1- amino-5-chloro-2,3- dihydrobenzo[b]furan-7-carboxamide; and
N-[(1-piperidyl)ethyl]-4-amino-5-chloro-2,
3- dihydrobenzo[b]furan-7-carboxamide;
if the case either as a single isomer or as a mixture of isomers, and the pharmaceutically acceptable salts thereof.
4. A compound as claimed in claim 2 or 3 for use as a 5HT4 receptor agonist.
5. A compound as claimed in claim 1, 2 OR 3 for use as a 5-HT4 receptor agonist in the treatment of a pathology wherein stimulation of a 5-HT4 receptor is needed.
6. A compound as claimed in claim 1, 2 or 3 for use as a therapeutic prokinetic agent in the treatment of gastrointestinal disorders.
7. A compound as claimed in claim 6 wherein the gastrointestinal disorder is dyspepsia, gastro- oesophageal reflux disease (GORD) or gastroparesis.
8. A compound as claimed in claim 1, 2 or 3 for use as a cognition activator in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
9. Use of a compound as defined in claim 1, 2, or 3 in the preparation of a medicament for use as a 5HT4 receptor agonist.
10. A process for preparing a dihydrobenzofuran
derivative of formula (I) as defined in claim 1 or 2, or a pharmaceutically acceptable salt thereof, said process comprising:
A) reacting of a compound of formula (II)
wherein
E is OH, Cl, Br or 1-imidazolyl, and
R1, R2 and R3 are, each independently, hydrogen,
C1-C6 alkyl, halogen, hydroxy, C1-C4 alkoxy, amino, C1-C4 alkylamino or C1-C4 di-alkylamino,
with an amine or an alcohol of formula (III), (IV) or (V)
wherein
Q is OH or NH2;
n is 1, 2, 3 or 4;
m is 0 or 1;
q is 0,1 or 2; and
R4 is hydrogen, C1-C6 alkyl, benzyl, cyclohexylmethyl or -CH2-CH2-SO2NH-R6 in which R6 is C1-C6 alkyl or benzyl, so obtaining a compound of formula (I) wherein R1 , R2, R3 and R6 are as defined above, X is NH or 0 and Z is a group (a), (b) or (c); or
B) reacting a compound of formula (VI)
wherein
Y is OH, Cl, Br or CH3-NH-OCH3, and R1, R2 and R3 are are as defined above,
with an organometallic derivative of formula (VII) , (VIII) or (IX)
wherein
M is MgBr, MgCl or Li, and
n, m, q, R4 and R5 are as defined above,
so obtaining a compound of formula (I) wherein R17 R2 and R3 are as defined above, X is CH2 and Z is a group (a), (b) or (c); or
C) reacting a compound of formula (X)
wherein
R1, R2, R3 and X are as defined above, and
X is NH, O or CH2,
with an alkyl halide of formula R5T wherein R5 is C1-C6 alkyl and T is halogen, so obtaining a compound of formula (I) wherein R1, R2, and R3 are as defined above, X is O, NH or CH2 and Z is a group (d); and, if desired, when a compound of formula (I) contains an asymmetric carbon atom,
D) resolving the racemic mixture of a compound of formula (I) into the single isomers; and/or, if desired,
E) converting a compound of formula (I) into a
pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a carrier and/or a pharmaceutically acceptable diluent and, as an active substance, a compound as defined in claim 1, 2 or 3.
12. A pharmaceutical composition according to claim 11, for use in the treatment of a pathology wherein
stimulation of a 5HT4 receptor is needed.
13. A pharmaceutical composition according to claim 11, for use as a therapeutic prokinetic agent in the
treatment of gastrointestinal disorders.
14. A pharmaceutical composition according to claim 13 wherein the gastrointestinal disorder is dyspepsia, gastro-oesophageal reflux disease (GORD) or
gastroparesis.
15. A pharmaceutical composition according to claim 11 for use as a cognition activator in the treatment of CNS disorders characterized by learning and/or memory dysfunctions.
EP96912004A 1995-04-18 1996-04-04 Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists Withdrawn EP0766680A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9507882.0A GB9507882D0 (en) 1995-04-18 1995-04-18 Substituted dihydrobenzofuran derivatives as 5-ht4 agonists
GB9507882 1995-04-18
PCT/EP1996/001482 WO1996033186A1 (en) 1995-04-18 1996-04-04 Substituted dihydrobenzofuran derivatives as 5-ht4 agonists

Publications (1)

Publication Number Publication Date
EP0766680A1 true EP0766680A1 (en) 1997-04-09

Family

ID=10773159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96912004A Withdrawn EP0766680A1 (en) 1995-04-18 1996-04-04 Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists

Country Status (4)

Country Link
EP (1) EP0766680A1 (en)
JP (1) JPH10502095A (en)
GB (1) GB9507882D0 (en)
WO (1) WO1996033186A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW445263B (en) 1996-02-29 2001-07-11 Janssen Pharmaceutica Nv Novel esters of 1,4-disubstituted piperidine derivatives
TW548103B (en) 1997-07-11 2003-08-21 Janssen Pharmaceutica Nv Bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
WO1999058527A2 (en) * 1998-05-14 1999-11-18 EGIS Gyógyszergyár Rt. Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
TW570920B (en) * 1998-12-22 2004-01-11 Janssen Pharmaceutica Nv 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
MXPA03006998A (en) * 2001-02-05 2004-10-15 Michael Albert Kamm A treatment of oesophageal motility disorders and gastro-oesophageal reflux disease.
AR036041A1 (en) 2001-06-12 2004-08-04 Upjohn Co HETEROCICLIC AROMATIC COMPOUNDS REPLACED WITH QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR036040A1 (en) 2001-06-12 2004-08-04 Upjohn Co MULTICICLIC HETEROARYL COMPOUNDS REPLACED WITH QUINUCLIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
PL369895A1 (en) 2001-10-02 2005-05-02 Pharmacia & Upjohn Company Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2466344A1 (en) 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
US6858613B2 (en) 2002-02-19 2005-02-22 Pfizer Inc. Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
JP2005523287A (en) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Azabicyclo compounds for disease treatment
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
AU2011256287B2 (en) 2010-05-17 2016-11-10 Envivo Pharmaceuticals, Inc. A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
RU2017136693A (en) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. METHODS FOR MAINTAINING, TREATING OR IMPROVING COGNITIVE FUNCTION

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122528A (en) * 1983-12-22 1992-06-16 Erbamont, Inc. Analgesic use of benzobicyclic carboxamides
JPH0649700B2 (en) * 1987-07-21 1994-06-29 吉富製薬株式会社 Benzofuran compound
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
AU667874B2 (en) * 1992-02-06 1996-04-18 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
CA2139503A1 (en) * 1993-05-06 1994-11-24 Christy S. John Compounds for cancer imaging and therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9633186A1 *

Also Published As

Publication number Publication date
JPH10502095A (en) 1998-02-24
GB9507882D0 (en) 1995-05-31
WO1996033186A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
US4826838A (en) Analgesic carbocyclic and heterocyclic carbonylmethylene-and carbonylmethypipidines and-pyrrolidines
US5554627A (en) Tachykinin antagonists
EP0766680A1 (en) Substituted dihydrobenzofuran derivatives as 5-ht 4 agonists
KR100263414B1 (en) Thieno [3,2-b] pyridine derivatives
CN103889981B (en) Tricyclic compound as anticarcinogen
SU1739849A3 (en) Method for synthesis of benzamide derivatives or their pharmacologically acceptable salts
NZ243993A (en) Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
SK281813B6 (en) Tropane-derivatives, their preparation and use
IL109234A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
JPH0363280A (en) Oxadiazole, its salts, therapeutic application thereof for treating dementia, method of preparation thereof and prescribed agent thereof
FR2696178A1 (en) Quaternary basic amides, process for their preparation and pharmaceutical compositions containing them
EP0339950A2 (en) Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof
EP0625149A1 (en) Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
CA2146923A1 (en) Heterocyclic condensed benzoic acid derivatives as 5-ht4 receptor antagonists
EP0496064B1 (en) Process for the preparation of substituted benzofuran derivatives
FI97806C (en) Process for the preparation of therapeutically active dihydrobenzofuran carboxamides
RU2418794C2 (en) Isoquinoline and benzo[h]isoquinoline derivatives, their obtaining and their application in therapy as antagonists of histamine h3 receptor
AU706980B2 (en) Diarylalkenylamine derivatives
JPH08502283A (en) 5-HT 4) Fused ring system N-alkylpiperidinyl-4-methylcarboxylic acid ester / amide for receptor antagonist
CA2060965A1 (en) Piperidine derivatives
RU2102392C1 (en) Piperidylmethyl-substituted chroman derivatives and their salts with inorganic acids
US5246942A (en) Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
HUT54151A (en) Process fopr producing new (r)-(-)-3-quinuclidinone derivatives and pharmaceutical compositions comprising such compounds
EA009059B1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP0737677A1 (en) 4-Indolylpiperazinyl derivates

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19961204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE GB IT

17Q First examination report despatched

Effective date: 19980217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980630